Platelet count, increased

Lab test abnormalities Increased platelet count increased transaminases and increased liver enzymes (eg, ALT, AST) were usually asymptomatic and reversible. Special senses - Visual adverse events most often included blurred vision, diplopia, or difficulty focusing. 

In conclusion, induced, moderate hypothermia can decrease ICP, reduce mortality, and may improve outcome in patients with severe MCA infarction with malignant postischemic brain edema. Important side effects are reduction of platelet count, increased rate of pneumonia, and elevation of serum amylase and lipase levels. The results of our own pilot trial suggest a beneficial effect of moderate hypothermia in the treatment of severe space-occupying MCA infarction. However, our data call for a randomized trial of hypothermia in the therapy of malignant MCA infarction. Whether early hypothermic therapy within the first 6 h after onset of symptoms can reduce infarct size has to be clarified in further clinical trials. 

A 54-year-old white woman took a 10-day course of co-trimoxazole (trimethoprim 160 mg, sulfamethoxazole 800 mg) for chronic sinusitis. One day after finishing the course she developed scattered petechiae on both hands and blood blisters in her mouth. She had a low platelet count of 20 x 10 /1. Other laboratory tests were normal, except for a raised blood glucose concentration. She was treated successfully with a transfusion of two units of platelets and oral prednisone. Four days after withdrawal of co-trimoxazole her platelet count increased to 110 x 10 /1. 

Severe acute respiratory syndrome (SARS) is an emerging, sometimes fatal, respiratory illness. The first identified cases occurred in China during 2002. Some experts believe that a virus causes SARS however, the specific agent remains unidentified. No laboratory or other test can definitively identify cases. Most suspected SARS cases occurring in the United States involved individuals returning from travel to Asia and healthcare staff members in contact with patients. Casual contact does not appear to cause SARS. Transmission appears to occur primarily through close contact with a symptomatic patient. Signs of illness include a decreased white blood cell count in most patients as well as below-normal blood platelet counts, increased liver enzymes, and electrolyte disturbances in a number of patients. 

Thrombopoietic factors (no recombinant TPO product in clinical use at this time IL-11 [recombinant product oprelvekin] has marketing approval) stimulate the production of megakaryocyte precursors, megakaryocytes, and platelets [8]. Interleukin-11 has many effects on multiple tissues, and can interact with IL-3, TPO, and SCF. AMG 531, a recombinant peptibody in that binds to the thrombopoetin receptor Mpl and stimulates the production of platelets, is in phase 1 and 2 studies and has been shown to safely increase platelet counts in patients with immune thrombocytopenic purpura [9]. 

FAT EMULSIONS. When a fat emulsion is administered, the nurse must monitor the patient s ability to eliminate the infused fat from the circulation. The lipidemia must clear between daily infusions. The nurse monitors for lipidemia through assessing the result of the following laboratory exams hemogram, blood coagulation, liver function tests, plasma lipid profile, and platelet count. The nurse reports an increase in any of these laboratory examinations as abnormal. 

Anti-Rh(D) can be used only in Rh(D)-positive patients. It is equal to TVIG in terms efficacy and generally is less expensive. The indications for use of anti-Rh(D) are identical to those for TVIG. Anti-D is especially desirable form of treatment in chronic ITP when the goal is to circumvent long-term exposure to corticosteroids. At doses of 25 mcg/kg per day, anti-Rh(D) may increase the platelet count in about 80% of children with acute and chronic HP. Substantial numbers of patients treated repetitively with Rh(D) can postpone or avoid splenectomy. 

Common side effects include increased blood pressure, increased respiratory infections and increased platelet counts. Serious (rare) side effects were most often related to cardiovascular complications. Neorecormon is marketed by Roche. 

Sequential determination of platelet counts in patients receiving vincristine during early studies unexpectedly occasionally revealed thrombocytosis, which could not be accounted for by systemic response to treatment alone 10,11). Ultimately shown to most likely be the result of increased megakaryocytic endomitosis II), the observation led to the use of vincristine, and later vinblastine, both alone and bound to platelets, in a variety of thrombocytopenic disorders. These include idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and chemotherapy-induced microangiopathic hemolytic anemia. 

The number of circulating blood platelet is markedly reduced by injection of a lethal dose of toxin-LR into mice ( 7 ). The time course of the decrease of the blood platelets is closely paralleled by the increase in fresh weight of the liver. The sharp rise in Spearman s rank correlation between platelet count and liver weight 30 minutes after injection indicates that thromocytopenia and hepatomegaly were almost concurrent. 

Exposure to 782 ppm for 4 weeks caused an increase in platelet counts in male rats and an increase in total leukocyte count in female rats hematologic parameters did not change for mice or rabbits exposed to the same or higher concentrations. Despite its chemical similarity, ethyl benzene does not appear to cause the same damage to the hematopoietic system as benzene. ... 

Perform complete blood count with differential and platelet counts regularly. Modest increases have occurred in platelets and white blood cell counts, but... 

Interruption of therapy - In general, interruption of anagrelide treatment is followed by an increase in platelet count. After sudden discontinuation of therapy, the increase in platelet count can be observed within 4 days. 

Increased prothrombin time, partial thromboplastin time, platelet aggregation time, platelet count, and factors II, VII, VIII, IX, X, XII, Vll-X complex, ll-VII-X complex, and -thromboglobulin decreased antithrombin III, antifactor Xa increased fibrinogen, plasminogen, norepinephrine-induced platelet aggregability. 

Mild to moderate neutropenia increased platelet count intermittent eosinophilia 0.5 1.5... 

Hematologic/Lymphatic Anemia hemolytic anemia thrombocytopenia thrombocytopenic purpura eosinophilia leukopenia granulocytopenia neutropenia bone marrow depression agranulocytosis reduction of hemoglobin or hematocrit prolongation of bleeding and prothrombin time decrease in WBC and lymphocyte counts increase in lymphocytes, monocytes, basophils, and platelets. Hypersensitivity Adverse reactions (estimated incidence, 1% to 10%) are more likely to occur in individuals with previously demonstrated hypersensitivity. In penicillin-sensitive individuals with a history of allergy, asthma, or hay fever, the reactions may be immediate and severe. 

Clarithromycin Adverse reactions occurring in at least 3% of patients include abdominal pain, abnormal taste, diarrhea, increased BUN, nausea, and rash. Dirithromycin Adverse reactions occurring in at least 3% of patients include abdominal pain/discomfort, diarrhea/loose stools, headache, increased platelet counts, nausea, and vomiting. 

Erythromycin Adverse reactions occurring in at least 3% of patients include abdominal pain/discomfort, diarrhea/loose stools, headache, increased platelet count, and nausea. 

Monitoring Periodic monitoring for toxicity, including CBC with differential and platelet counts, and liver and renal function testing is mandatory. Periodic liver biopsies may be indicated in some situations. Monitor patients at increased risk for impaired methotrexate elimination (eg, renal dysfunction, pleural effusions, ascites) more frequently (see Precautions). 

---